chronic
gvhd
cgvhd
still
major
complic
longterm
survivor
allohsct
probabl
patient
receiv
owe
increas
number
allohsct
use
pbsc
mismatch
unrel
donor
clinic
applic
donor
lymphocyt
infus
allohsct
elderli
young
patient
cgvhd
becom
even
common
seriou
challeng
clinic
followup
transplant
addit
relat
mortal
sever
survey
show
activ
cgvhd
markedli
reduc
qualiti
life
patient
suffer
moder
sever
pulmonari
complic
significantli
contribut
late
mortal
allohsct
patient
surviv
longer
year
bathia
et
found
increas
risk
late
mortal
pulmonari
dysfunct
compar
gener
popul
furthermor
lateonset
noninfecti
pulmonari
complic
present
restrict
lung
function
impair
restrict
pulmonari
function
test
pft
pattern
late
interstiti
pneumon
ip
cryptogen
organ
pneumonia
cop
also
call
bronchiol
obliteran
organ
pneumonia
boop
airway
obstruct
obstruct
pft
pattern
bronchiol
obliteratan
bo
bo
syndrom
bo
combin
lateonset
noninfecti
pulmonari
complic
form
strongli
associ
cgvhd
pathophysiolog
fulli
howev
bobo
pulmonari
complic
current
consid
diagnost
wherea
boop
also
detect
acut
gvhd
therefor
regard
common
symptom
gvhd
late
ip
well
cop
may
occur
associ
cgvhd
regard
associ
symptom
cgvhd
bobo
detriment
posttranspl
late
pulmonari
complic
character
frequent
nonrespons
treatment
irrevers
lead
high
morbid
mortal
comprehens
review
entiti
recent
publish
william
et
consensu
confer
clinic
practic
chronic
gvhd
held
regensburg
germani
novemb
http
wwwgvhdeu
aim
summar
current
avail
evid
diagnosi
immunosuppress
support
treatment
pulmonari
manifest
provid
practic
guidelin
use
treatment
modal
consensu
confer
organ
auspic
german
work
group
bm
blood
stem
cell
transplant
dagkbt
german
societi
hematolog
oncolog
dgho
austrian
stem
cell
transplant
work
group
austrian
societi
hematolog
oncolog
swiss
blood
stem
cell
transplant
group
sbst
germanaustrian
pediatr
work
group
sct
base
review
publish
evid
two
survey
current
clinic
practic
diagnosi
treatment
cgvhd
includ
bo
total
transplant
center
germani
austria
switzerland
particip
survey
moreov
consensu
circul
among
transplant
center
perform
allohsct
germani
austria
switzerland
discuss
consensu
confer
meet
literatur
search
perform
work
group
firstlin
treatment
within
consensu
confer
use
pubm
databas
english
literatur
consid
abstract
bone
marrow
transplant
tandem
meet
european
bone
marrow
transplant
meet
american
societi
hematolog
meet
cite
includ
evid
rate
evalu
evid
subsequ
recommend
grade
accord
system
use
grade
support
care
publish
couriel
et
evid
major
treatment
option
cgvhd
spars
therefor
strength
recommend
fall
categori
c
therapeut
option
categori
c
evid
iii
level
specifi
shown
tabl
strength
recommend
evid
level
first
rate
expert
panel
subsequ
rate
particip
consensu
process
evid
use
cgvhd
includ
evalu
follow
discuss
diagnost
criteria
screen
method
system
topic
immunosuppress
treatment
option
pulmonari
manifest
cgvhd
mainli
focu
report
clinic
trial
retrospect
analys
present
overview
current
evid
herein
deduc
recommend
consensu
confer
particip
intend
provid
platform
collabor
effort
order
plan
pursu
clinic
trial
direct
diseas
pathophysiolog
treatment
outcom
earli
stage
patient
pulmonari
cgvhd
either
asymptomat
often
present
nonspecif
nondiagnost
symptom
mild
dyspnea
exert
dri
nonproduct
cough
owe
initi
lack
patient
percept
diseas
detect
diseas
usual
delay
airflow
pattern
lung
structur
significantli
chang
patient
suffer
signific
dyspnea
exert
decreas
exercis
toler
exhibit
emin
persist
nonproduct
cough
fever
indic
associ
infect
dyspnea
product
vs
nonproduct
cough
found
combin
pulmonari
diseas
progress
eventu
oxygen
depend
immobl
death
occur
mainli
associ
pulmonari
infecti
complic
basi
patient
delay
percept
nonspecif
clinic
symptom
find
physic
examin
standard
approach
necessari
detect
pulmonari
cgvhd
earli
irrevers
structur
chang
occur
addit
infecti
caus
need
rule
best
extent
proof
underli
viral
bacteri
fungal
diseas
requir
target
antimicrobi
antivir
treatment
wherea
pulmonari
cgvhd
start
intensifi
immunosuppress
mainstay
therapi
often
contraind
presenc
infect
therefor
follow
medic
histori
laboratori
workup
suggest
donor
type
unrel
vs
sibl
hla
matchmismatch
use
tbi
bu
histori
donor
lymphocyt
infus
donor
patient
gender
femal
recipi
patient
age
cmv
seroposit
donor
recipi
histori
smoke
allergi
chronic
infecti
complic
lung
diseas
thorac
irradi
prehsct
histori
acut
lung
injuri
follow
allohsct
histori
cgvhd
site
complet
wbc
count
includ
differenti
eosinophilia
serum
ig
level
igg
iga
thorough
physic
examin
includ
heart
lung
perform
patient
visit
includ
evalu
sign
symptom
cgvhd
site
addit
echocardiographi
address
pulmonari
arteri
pressur
standard
oxygen
assess
suggest
current
guidelin
american
thorac
societi
exampl
test
pft
spirometri
wholebodi
plethysmographi
singlebreath
co
method
noninvas
easytodo
approach
assess
pulmonari
function
follow
allohsct
earli
childhood
cooper
often
limit
reliabl
pft
result
achiev
age
year
babi
plethysmographi
sedat
rare
necessari
option
test
pulmonari
function
infant
despit
appar
respiratori
symptom
mani
patient
develop
normaltomild
restrict
normal
reduc
forc
expiratori
vital
capac
fvc
total
lung
capac
tlc
combin
increas
residu
volum
rv
tlc
ratio
normal
mildli
reduc
flow
rate
suggest
function
structur
chang
occur
clinic
symptom
physic
impair
becom
impair
pulmonari
function
reflect
either
decreas
tlc
fvc
diffus
capac
lung
carbon
monoxid
forc
expiratori
volum
increas
calcul
lung
function
score
lf
day
post
sct
associ
higher
mortal
decreas
specif
bobo
nation
institut
health
consensu
defin
mild
bobo
often
asymptomat
manifest
cgvhd
alreadi
requir
system
moder
moderatetosever
organ
manifest
impair
physic
function
decreas
qualiti
bobo
occur
time
mostli
first
year
follow
allosct
order
identifi
patient
risk
pulmonari
cgvhd
detect
manifest
subclin
diseas
earli
screen
seem
justifi
made
consensu
recommend
group
also
recommend
nation
institut
health
ancillari
therapi
support
care
work
success
screen
may
easili
warrant
use
standard
lung
function
analysi
approach
follow
approach
may
consid
baselin
pft
within
last
week
start
condit
therapi
followup
everi
month
first
year
transplant
everi
month
addit
pft
need
patient
present
respiratori
symptom
absenc
acut
pulmonari
infect
week
initi
treatment
follow
patholog
pft
indic
restrict
spirometr
pattern
vc
tlc
fvc
predict
valu
combin
forc
expiratori
volum
first
second
expir
fvc
although
restrict
lung
function
chang
easili
quantifi
pft
patient
allohsct
correct
assess
true
airflow
obstruct
deleteri
form
bo
difficult
accord
current
guidelin
atser
taskforc
use
measur
sever
obstruct
well
restrict
chang
pulmonari
function
concur
decreas
patient
follow
allohsct
multipl
factor
condit
regimen
toxic
sclerodermalik
cgvhd
steroid
treatmentrel
myopathi
lead
intrins
extrins
pulmonari
restrict
appli
ratio
paramet
obstruct
airway
diseas
valu
appear
fals
normal
despit
manifest
pulmonari
obstruct
presenc
signific
declin
higher
per
year
combin
demonstr
indic
airflow
obstruct
follow
therefor
suggest
valu
compar
time
order
detect
oblit
airway
diseas
earli
time
point
pulmonari
damag
may
still
revers
patient
revers
obstruct
chang
address
effect
bronchodil
administr
signific
bronchodil
respons
fvc
increas
l
prebronchodil
addit
combin
predict
normal
combin
may
higher
valid
pft
indic
bo
paramet
children
measur
effect
resist
reff
addit
use
indic
mild
predict
normal
intermedi
sever
restrict
ventilatori
disord
transfer
factor
lung
carbon
monoxid
tlco
diffus
capac
measur
abil
exchang
gase
alveolar
capillari
interfac
reflect
alveolar
membran
thick
howev
may
affect
hb
level
well
cardiac
output
show
highest
variabl
laboratori
pediatr
popul
correct
hb
level
gener
recommend
furthermor
reproduc
tlco
measur
feasibl
age
year
expir
time
sec
need
test
requir
optim
cooper
relev
tlco
decreas
allohsct
unclear
declin
tlco
appar
hsct
survivor
may
reflect
damag
subclin
fibrosi
associ
improv
decreas
surviv
associ
report
lung
function
score
lf
combin
tlco
equal
distribut
manner
tlco
correct
hb
level
summari
score
ii
iii
iv
lf
first
propos
parimon
et
potenti
better
approach
correl
pft
allohsct
clinic
outcom
revisit
modifi
precis
subdivid
subcategori
nation
institut
health
consensu
develop
project
criteria
clinic
trial
cgvhd
suggest
score
quantifi
pulmonari
cgvhd
evalu
effect
cgvhd
treatment
valid
lf
exist
children
far
henc
lf
recommend
tool
evalu
pulmonari
cgvhd
childhood
time
lf
valid
yet
propos
form
suggest
inclus
followup
everi
adult
patient
set
evalu
diagnost
option
seem
measur
fraction
exhal
nitric
oxid
shown
potenti
predict
valu
bo
howev
differ
agedepend
norm
valu
consid
adult
normal
ppb
intermedi
ppb
high
ppb
children
normal
ppb
intermedi
ppb
high
ppb
rise
sinc
previou
measur
fraction
exhal
nitric
oxid
measur
usual
perform
age
year
portabl
devic
perform
survey
diagnosi
cgvhd
half
particip
center
state
perform
lung
function
screen
asymptomat
patient
result
consensu
confer
center
agre
establish
routin
pulmonari
function
test
certain
time
point
fact
symptomat
bo
alreadi
significantli
interfer
qualiti
life
physic
function
therefor
screen
asymptomat
patient
requir
convent
chest
xray
present
fast
easi
method
determin
likelihood
infecti
vs
noninfecti
etiolog
classic
radiograph
sign
lobar
bronchial
bacteri
pneumonia
present
match
clinic
find
howev
sensit
specif
limit
compar
chest
ct
latter
altern
consid
accord
clinic
set
institut
polici
noninfecti
lung
injuri
suspect
differenti
viral
fungal
pneumonia
necessari
highresolut
chest
comput
tomographi
hrct
recommend
standard
imag
techniqu
address
lung
injuri
adult
sct
recipi
young
children
age
year
sedat
necessari
perform
chest
ct
make
evalu
inspir
expir
difficult
therefor
earli
multislic
ct
scan
possibl
expir
may
consid
children
long
lung
injuri
progress
may
increas
risk
sedat
case
cop
boop
patchi
consolid
groundglass
attenu
seen
characterist
expiratori
hrct
studi
cooper
patient
help
assess
obstruct
lung
injuri
present
bronchial
dilat
mosaic
pattern
attenu
air
trap
correl
pft
paramet
includ
rv
tlco
tlc
furthermor
hrct
provid
inform
regard
potenti
infecti
etiolog
lung
injuri
demonstr
higher
specif
fungal
vs
viral
bacteri
patient
clinic
symptom
sinu
infect
suspect
sinobronchi
syndrom
ct
sinus
suggest
explor
potenti
foci
drive
pulmonari
infect
may
also
strongli
consid
even
younger
children
survey
diagnosi
cgvhd
one
particip
center
state
perform
routin
hrct
scan
patient
drop
suspicion
pulmonari
cgvhd
respiratori
symptom
patholog
find
hrct
requir
workup
bronchoalveolar
lavag
bal
defin
exclud
caus
infecti
agent
bal
recommend
earli
patient
variou
reason
proof
exclus
infect
significantli
effect
subsequ
therapi
pulmonari
function
may
rapidli
declin
invas
ventil
support
may
becom
necessari
suggest
bal
cytolog
analysi
incorpor
absolut
cellular
well
leukocyt
subpopul
ratio
atyp
epitheli
cell
morpholog
screen
infect
commonli
involv
stain
cultur
andor
pcr
bacteria
virus
fungi
specif
pathogen
interest
includ
pneumococci
haemophilu
influenza
b
chlamydia
pneumonia
mycoplasma
pneumonia
toxoplasma
gondii
bordetella
pertussi
mycobaterium
tuberculosi
mycobacteria
tuberculosi
pneumocysti
jirovecii
adenoviru
cmv
human
metapneumoviru
influenza
ab
parainfluenza
coronaviru
rhinoviru
respiratori
syncyti
viru
aspergillu
speci
individu
case
panbacteri
panfung
pcr
screen
may
indic
control
studi
benefit
risk
valu
bal
patient
pulmonari
cgvhd
report
yet
howev
bal
shown
well
toler
safe
procedur
even
pediatr
popul
high
inform
valu
patient
acut
pulmonari
dysfunct
follow
seem
also
safe
applic
patient
later
time
point
survey
diagnosi
cgvhd
onethird
particip
center
state
perform
bal
patient
drop
radiolog
sign
pulmonari
cgvhd
present
major
center
state
perform
bal
diagnost
procedur
definit
diagnosi
differ
form
pulmonari
cgvhd
need
histopatholog
confirm
transbronchi
biopsi
may
help
diffus
lung
patholog
typic
hrct
find
groundglass
appear
fibrosi
lesion
larger
cm
locat
close
proxim
major
bronchi
wherea
open
lung
biopsi
may
consid
patient
small
focal
process
locat
peripher
lung
parenchyma
although
transbronchi
biopsi
associ
low
sensit
rel
poor
predict
valu
valu
higher
patient
late
ip
contrast
open
lung
biopsi
remain
gold
standard
diagnosi
bo
copboop
time
associ
overal
morbid
day
procedur
result
sever
lifethreaten
complic
everi
seventh
therefor
decis
whether
transbronchi
open
lung
biopsi
may
perform
made
care
case
case
base
context
radiograph
find
risk
potenti
complic
expect
clinic
consequ
made
depend
upon
biopsi
result
still
pursu
consequ
survey
diagnosi
cgvhd
half
particip
center
state
perform
transbronchi
lung
biopsi
diagnost
workup
cgvhd
connect
need
experienc
secondopinion
pathologist
state
improv
qualiti
histolog
diagnosi
pulmonari
cgvhd
consensu
project
cgvhd
nation
institut
health
usa
provid
definit
bobo
primarili
base
pft
hrct
requir
follow
order
character
bobo
manifest
cgvhd
predict
normal
sign
air
trap
pft
rv
predict
normal
sign
air
trap
small
airway
thicken
bronchiectasi
expiratori
hrct
patholog
confirm
constrict
bronchiolitisabs
activ
respiratori
tract
infectionin
case
lack
histolog
proof
bo
least
one
distinct
manifest
cgvhd
addit
organ
system
requir
intern
consensu
confer
diagnosi
treatment
cgvhd
german
austrian
swiss
transplant
group
agre
appli
definit
clinic
routin
clinic
trial
pediatr
patient
howev
requir
cgvhd
involv
organ
besid
lung
absenc
histolog
proof
bo
may
seen
stringent
perform
biopsi
patient
often
clinic
imposs
isol
bo
observ
frequent
without
organ
less
stringent
modif
criteria
recent
propos
potenti
broaden
inclus
patient
clinic
earli
bo
bronchiolar
inflamm
shown
therefor
earli
treatment
may
prove
promis
initi
therapi
structur
fibrot
chang
occur
drop
within
last
year
combin
gold
air
trap
pft
hrct
found
pft
hrct
patient
lf
present
mild
clinic
symptom
indic
topic
treatment
tabl
given
bergeron
et
retrospect
analyz
role
topic
treatment
earli
cours
progress
airflow
obstruct
use
combin
budenosid
inhal
steroid
formoterol
longact
bronchodil
total
patient
mildtomoder
bo
treat
regimen
show
durabl
improv
clinic
pft
followup
month
month
combin
regimen
may
promis
approach
b
current
prospect
trial
evalu
efficaci
budesonid
formoterol
treatment
bo
allohsct
contrast
result
bo
lung
transplant
recent
publish
retrospect
analysi
inhal
highdos
fluticason
treatment
bo
allohsct
show
efficaci
group
howev
inhal
corticosteroid
ic
use
topic
antiinflammatori
treatment
recommend
children
fluticason
ciclesonid
may
consid
combin
shortact
betaagonist
salbutamol
rather
longact
betaagonist
latter
recommend
infant
toddler
survey
center
state
use
combin
inhal
system
steroid
wherea
six
center
appli
system
steroid
two
center
use
option
regard
use
inhal
bronchodil
seven
center
state
use
shortact
sympathomimet
inhal
agent
total
center
use
longact
sympathomimet
agent
eight
center
appli
parasympatholyt
agent
four
center
use
one
option
pediatr
adult
patient
use
dornas
alpha
may
consid
sinobrochi
syndrom
chronic
mucu
plug
suspect
mucociliari
dysfunct
present
lead
infect
bronchiectasi
case
chronic
bacteri
colon
airway
inhal
tobramycin
consid
pulmonari
hypertens
may
develop
chronic
restrict
airway
diseas
persist
patient
inhal
iloprost
may
therapeut
follow
treatment
patient
need
reevalu
improv
even
progress
diseas
observ
initi
system
immunosuppress
tabl
suggest
recommend
system
immunosuppress
therapi
may
also
start
upfront
patient
initi
present
moderatetosever
clinic
symptom
lf
ii
combin
airtrap
present
pft
hrct
firstlin
treatment
usual
involv
corticosteroid
exampl
prednisolon
mgkg
bodi
weight
ii
maximum
mg
prednisoloneday
plu
continu
immunosuppress
therapi
exampl
calcineurin
inhibitor
clinic
respons
observ
onefifth
altern
steroid
puls
treatment
prednisolon
dose
mgkg
bodi
weightday
day
appli
studi
median
number
four
cycl
given
interv
cycl
improv
month
treatment
diseas
progress
halt
patient
mean
followup
steroid
also
present
standard
firstlin
treatment
restrict
lateonset
noninfecti
pulmonari
complic
includ
copboop
late
ip
given
dose
least
prednisolon
mgkg
bodi
weight
ii
case
lead
improv
stabil
taper
steroid
usual
initi
week
treatment
howev
treatment
success
specif
bo
often
persist
immunosuppress
drug
immunomodulatori
approach
becom
necessari
extracorpor
photopheresi
report
success
treatment
cgvhd
includ
bo
sever
studi
also
treatment
respons
rate
restrict
obstruct
lung
involv
respect
interestingli
recent
studi
demonstr
respons
twothird
patient
suffer
refractori
bo
despit
median
number
five
treatment
howev
criteria
pulmonari
cgvhd
far
uniformli
defin
patient
number
gener
low
larger
prospect
studi
need
better
determin
role
extracorpor
photopheresi
treatment
cgvhdrelat
lung
diseas
although
efficaci
calcineurin
inhibitor
cya
tacrolimu
mammalian
target
rapamycin
inhibitor
sirolimu
everolimu
mycophenol
mofetil
shown
patient
bo
follow
lung
substanc
frequent
use
treatment
usag
drug
patient
bo
allohsct
remain
empir
clinic
trial
exist
replac
strategi
exampl
chang
cya
combin
approach
cya
plu
mycophenol
sirolimu
plu
mycophenol
may
prove
benefici
hsct
recipi
warrant
investig
howev
light
common
clinic
use
outsid
trial
patient
bo
allohsct
mainli
unchang
clinic
outcom
abil
efficaci
drug
significantli
alter
progress
cours
diseas
seen
critic
even
addit
immunosuppress
measur
need
balanc
increas
risk
opportunist
infect
small
case
seri
azithromycin
macrolid
antibiot
show
potenc
high
efficaci
low
toxic
treatment
bo
follow
lung
howev
one
report
publish
azithromycin
bo
follow
studi
patient
develop
bo
hsct
seven
allo
one
auto
treat
azithromycin
mg
qd
day
follow
mg
week
week
clinic
signific
improv
achiev
fvc
seven
eight
patient
therefor
azithromycin
provid
welltoler
therapeut
approach
recommend
routin
use
patient
mild
airflow
obstruct
addit
topic
therapi
recommend
continu
add
azithromycin
immunosuppress
cya
steroid
patient
moder
sever
obstruct
lung
diseas
although
mechan
action
azithromycin
fulli
understood
seem
lead
reduct
neutrophilc
also
function
prokinet
properti
upper
gastrointestin
tract
therebi
reduc
gastroesophag
reflux
recent
establish
risk
factor
interestingli
two
differ
form
bo
describ
discrimin
respons
azithromycin
respons
neutrophil
partial
revers
nonrespons
fibroprolif
research
may
aid
understand
whether
confer
neutrophil
vs
lymphocyt
form
bo
describ
two
decad
present
differ
stage
diseas
tnf
critic
factor
develop
acut
lung
injuri
follow
allohsct
neutral
significantli
improv
clinic
outcom
howev
role
tnf
develop
pulmonari
cgvhd
establish
antitnf
treatment
still
fulli
investig
far
success
use
tnf
blockad
report
case
report
infliximab
etanercept
late
use
remain
experiment
recommend
restrict
special
circumst
associ
infecti
risk
profibrot
cytokin
receptor
significantli
involv
pathophysiolog
bo
boop
fibrot
manifest
therefor
target
fibrosi
present
promis
therapeut
approach
led
use
tyrosin
kinas
inhibitor
imatinib
patient
pulmonari
cgvhd
base
antifibrot
majhail
et
report
one
patient
bo
demonstr
signific
durabl
respons
imatinib
dose
mg
daili
year
patient
combin
chronic
lung
injuri
imatinib
mg
daili
led
signific
improv
lung
function
follow
treatment
period
month
imatinib
combin
concurr
immunosuppress
studi
futur
may
prove
effici
addit
arm
treatment
patient
pulmonari
cgvhd
current
imatinib
may
consid
addit
agent
secondlin
treatment
bo
restrict
obstruct
form
lung
injuri
follow
allohsct
result
persist
dysregul
inflamm
leukotrien
eicosanoid
lipid
mediat
contribut
inflammatori
process
involv
develop
asthma
alveol
pulmonari
fibrosi
bo
follow
lung
transplant
promot
bronchoconstrict
well
eosinophil
neutrophil
preliminari
clinic
observ
demonstr
potenti
therapeut
efficaci
montelukast
leukotrien
receptor
antagonist
patient
bo
follow
current
test
ongo
nation
institut
health
phase
trial
addit
combin
treatment
fluticason
azithromycin
montelukast
demonstr
compar
efficaci
prednison
stabil
patient
bo
allow
signific
reduct
total
dose
prednison
exposur
therebi
may
proof
steroid
spare
treatment
altern
current
montelukast
may
consid
addit
agent
treatment
bo
tli
inhal
cya
present
treatment
option
success
use
small
number
patient
bo
lung
transplant
use
yet
report
patient
bo
therefor
use
treatment
modal
may
consid
experiment
use
clinic
trial
individu
case
medic
treatment
fail
prevent
progress
pulmonari
diseas
eventu
lung
transplant
therapeut
ultima
ratio
may
indic
sever
report
demonstr
clinic
efficaci
valu
procedur
adult
hsct
indic
lung
transplant
includ
progress
deterior
despit
immunosuppress
month
acut
respiratori
distress
total
depend
oxygen
support
sever
limit
exercis
life
qualiti
lack
oxygen
sever
pulmonari
hypertens
counterbalanc
gener
state
health
age
patient
transplantationassoci
limit
risk
relaps
infect
secondari
neoplasia
prolong
immunosuppress
follow
lung
transplant
survey
treatment
cgvhd
center
agre
central
role
system
steroid
treatment
pulmonari
gvhd
moreov
center
appli
puls
steroid
cours
bo
six
center
appli
time
diagnosi
pulmonari
cgvhd
four
center
use
second
line
calcineurin
inhibitor
appli
center
center
use
cya
center
use
also
tacrolimu
major
center
regard
calcineurin
inhibitor
second
thirdlin
treatment
option
mycophenol
mofetil
use
center
treatment
bo
major
appli
second
thirdlin
therapi
extracorpor
photopheresi
appli
center
treatment
bo
w
mainli
third
fourthlin
treatment
option
mammalian
target
rapamycin
inhibitor
sirolimu
center
everolimu
center
appli
mainli
failur
firstlin
treatment
regard
treatment
first
choic
two
center
imatinib
current
appli
four
center
advanc
treatment
line
etanercept
consid
six
center
mainli
third
fourthlin
treatment
azathioprin
pentostatin
infliximab
basiliximab
appli
center
diagnost
complex
vast
varieti
choic
algorithm
treatment
approach
center
reflect
current
dilemma
pulmonari
cgvhd
today
criteria
definit
cgvhd
lung
uniformli
appli
clinic
spectrum
reach
subclini
pft
chang
sever
lifethreaten
pulmonari
impair
knowledg
treat
rather
base
anecdot
experi
small
number
case
seri
singl
center
data
deriv
clinic
multicent
trial
treatment
may
often
start
late
time
point
irrevers
structur
remodel
pulmonari
parenchyma
occur
translat
conclus
recommend
consensu
statement
routin
diagnost
clinic
care
followup
patient
allohsct
figur
may
help
achiev
uniform
treatment
diseas
differ
hsct
center
therefor
allow
better
assess
respons
data
compar
experi
well
optim
patient
care
better
experiment
model
may
help
improv
understand
pulmonari
cgvhd
futur
clinic
multicent
trial
address
risk
factor
patient
manag
followup
well
evalu
specif
therapeut
option
eg
order
better
defin
role
extracorpor
photopheresi
vs
azithromycin
ad
treatment
option
firstlin
steroid
eagerli
need
